Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P04637
UPID:
P53_HUMAN
Alternative names:
Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53
Alternative UPACC:
P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61
Background:
Cellular tumor antigen p53, also known as Phosphoprotein p53 or Tumor suppressor p53, plays a pivotal role in preventing cancer formation. Through its ability to act as a tumor suppressor in various tumor types, p53 induces growth arrest or apoptosis depending on cell type and physiological circumstances. It is involved in cell cycle regulation, negatively regulating cell division by controlling genes required for this process.
Therapeutic significance:
Given its involvement in diseases such as Esophageal cancer, Li-Fraumeni syndrome, Squamous cell carcinoma of the head and neck, Lung cancer, and several others, targeting p53 for therapeutic intervention could revolutionize cancer treatment. Understanding the role of Cellular tumor antigen p53 could open doors to potential therapeutic strategies.